MOUNTAIN VIEW, Calif., July 27, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor events in August:
Wedbush Life Sciences MAC Best Ideas: Management Access Conference Tuesday, August 3, at 8:00 a.m. ET in New York, New York Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference Thursday, August 12, at 1:40 p.m. ET in Southampton, New York
A live webcast of the events will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX(TM) orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
CONTACTS: Lisa Borland MAP Pharmaceuticals, Inc. (650) 386-3122 firstname.lastname@example.org
SOURCE MAP Pharmaceuticals, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved